Literature DB >> 26676759

Myc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies.

Clare M Adams1, Scott W Hiebert2, Christine M Eischen3.   

Abstract

Alterations in the expression or function of histone deacetylases (HDAC) contribute to the development and progression of hematologic malignancies. Consequently, the development and implementation of HDAC inhibitors has proven to be therapeutically beneficial, particularly for hematologic malignancies. However, the molecular mechanisms by which HDAC inhibition (HDACi) induces tumor cell death remain unresolved. Here, we investigated the effects of HDACi in Myc-driven B-cell lymphoma and five other hematopoietic malignancies. We determined that Myc-mediated transcriptional repression of the miR-15 and let-7 families in malignant cells was relieved upon HDACi, and Myc was required for their upregulation. The miR-15 and let-7 families then targeted and downregulated the antiapoptotic genes Bcl-2 and Bcl-xL, respectively, to induce HDACi-mediated apoptosis. Notably, Myc also transcriptionally upregulated these miRNA in untransformed cells, indicating that this Myc-induced miRNA-mediated apoptotic pathway is suppressed in malignant cells, but becomes reactivated upon HDACi. Taken together, our results reveal a previously unknown mechanism by which Myc induces apoptosis independent of the p53 pathway and as a response to HDACi in malignant hematopoietic cells. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26676759      PMCID: PMC4738141          DOI: 10.1158/0008-5472.CAN-15-1751

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  BCL2 is a downstream effector of MIZ-1 essential for blocking c-MYC-induced apoptosis.

Authors:  Jagruti H Patel; Steven B McMahon
Journal:  J Biol Chem       Date:  2006-11-01       Impact factor: 5.157

Review 2.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.

Authors:  Peter E Czabotar; Guillaume Lessene; Andreas Strasser; Jerry M Adams
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01       Impact factor: 94.444

3.  Down-regulation of bcl-2 by p53 in breast cancer cells.

Authors:  S Haldar; M Negrini; M Monne; S Sabbioni; C M Croce
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

Review 4.  New and emerging HDAC inhibitors for cancer treatment.

Authors:  Alison C West; Ricky W Johnstone
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 5.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

6.  Oncogenic protein MTBP interacts with MYC to promote tumorigenesis.

Authors:  Brian C Grieb; Mark W Gramling; Maria Pia Arrate; Xi Chen; Stephen L Beauparlant; Dale S Haines; Hua Xiao; Christine M Eischen
Journal:  Cancer Res       Date:  2014-05-01       Impact factor: 12.701

Review 7.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

8.  Miz1 is required to maintain autophagic flux.

Authors:  Elmar Wolf; Anneli Gebhardt; Daisuke Kawauchi; Susanne Walz; Björn von Eyss; Nicole Wagner; Christoph Renninger; Georg Krohne; Esther Asan; Martine F Roussel; Martin Eilers
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.

Authors:  T D Littlewood; D C Hancock; P S Danielian; M G Parker; G I Evan
Journal:  Nucleic Acids Res       Date:  1995-05-25       Impact factor: 16.971

10.  HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.

Authors:  J E Bolden; W Shi; K Jankowski; C-Y Kan; L Cluse; B P Martin; K L MacKenzie; G K Smyth; R W Johnstone
Journal:  Cell Death Dis       Date:  2013-02-28       Impact factor: 8.469

View more
  26 in total

1.  Effect of BCLAF1 on HDAC inhibitor LMK-235-mediated apoptosis of diffuse large B cell lymphoma cells and its mechanism.

Authors:  Xinyao Li; Zhengchang He; Bingqing Cheng; Qin Fang; Dan Ma; Tingting Lu; Danna Wei; Xingyi Kuang; Sishi Tang; Jie Xiong; Jishi Wang
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

2.  RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs.

Authors:  Ruixi Hu; Xiaodong Zhu; Chao Chen; Ruijun Xu; Yifan Li; Wei Xu
Journal:  Cell Prolif       Date:  2018-08-07       Impact factor: 6.831

3.  Molecular underpinnings of HDAC inhibition revealed.

Authors:  Clare M Adams; Christine M Eischen
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

4.  BCL-W has a fundamental role in B cell survival and lymphomagenesis.

Authors:  Clare M Adams; Annette S Kim; Ramkrishna Mitra; John K Choi; Jerald Z Gong; Christine M Eischen
Journal:  J Clin Invest       Date:  2017-01-17       Impact factor: 14.808

5.  Smarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress.

Authors:  Matthew V Puccetti; Clare M Adams; Saul Kushinsky; Christine M Eischen
Journal:  Cancer Res       Date:  2019-01-04       Impact factor: 12.701

Review 6.  Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Nikolaos Charalampakis; Leon Naar; Maria Ioannidi; Diamantis Tsilimigras; Maria Sotiropoulou; Dimitrios Moris; Pantelis Vassiliu; Evangelos Felekouras
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

7.  HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.

Authors:  Cancan Luo; Tiantian Yu; Ken H Young; Li Yu
Journal:  J Zhejiang Univ Sci B       Date:  2022-08-15       Impact factor: 5.552

8.  Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia.

Authors:  Jiajia Li; Meng Wang; Xiaofeng Chen
Journal:  Cell Cycle       Date:  2020-04-14       Impact factor: 4.534

9.  Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.

Authors:  Clare M Adams; Ramkrishna Mitra; Jerald Z Gong; Christine M Eischen
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

Review 10.  The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.

Authors:  Renumathy Dhanasekaran; Anja Deutzmann; Wadie D Mahauad-Fernandez; Aida S Hansen; Arvin M Gouw; Dean W Felsher
Journal:  Nat Rev Clin Oncol       Date:  2021-09-10       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.